Assess the Feasibility of Cone Beam CT to Localize Liver Metastases Immediately Prior to Radiotherapy

Completed · Not applicable

Conditions studied: Localize Liver Metastases

In brief

The purpose of this study is to test a new and possibly more accurate method of positioning patients with liver tumors in preparation for radiation treatment. The positioning of patients with liver cancer is important because the tumor moves a bit when you breathe and makes it hard to determine the right position of the tumor at the time of treatment. Also, depending upon what is in your stomach at the time of treatment, it may change the shape of the liver and make it difficult to plan the radiation treatment. As part of this study, we will take a new type of image of your liver in addition to the standard portal images. This new type of image is called a cone-beam image. It shows a much more detailed picture of the liver tumors than the standard portal images. Normally, marker seeds need to be placed near the liver metastasis for radiation treatment. If the results of this study show that the tumor can be positioned as accurately with the new images as with the old images, then future patients with liver tumors would not have to have marker seeds placed into their liver. The use of cone beam imaging for the setup of patients with liver tumors is new.

Key facts

Study ID

NCT00600613

Run by

Memorial Sloan Kettering Cancer Center

People needed

6

Starts

2006-01-01

Expected to finish

2010-10-01

Last updated by the study team

2015-05-07

Who can join

Age: 18 and older, up to 95. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > than or equal to 18 years
• KPS > than or equal to 80
• Able to tolerate immobilization cradle positioning
• Able to give informed consent
• Histologically confirmed diagnosis of solid tumor malignancy
• Liver metastases visualized on CT imaging

You may not qualify if…

• Lymphoid primary histology (lymphoma/leukemia)
• Allergic reaction to intravenous CT contrast
• Liver function tests (AST, ALT, Bilirubin) > 2.0 x normal
• Abnormal kidney function (serum creatinine > 1.5)
• INR > 2.0, Platelet count <70.000.
• Marker seed placement not possible
• > 5mm excursion after abdominal compression

Where it is running

• Memorial Sloan Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.